Our findings demonstrate that EP can exert antitumor activity in multiple myeloma U266 cells by anti-angiogenic activity targeting JAK2/STAT3 signaling pathway as a potent anti-cancer agent for multiple myeloma treatment. This evidence concerns the gene JAK2 and plasma cell myeloma.